Alvotech (ALVO) Expected to Announce Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to release its Q4 2025 results after the market closes on Wednesday, March 18th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $162.1950 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 8:00 AM ET.

Alvotech Stock Up 4.0%

ALVO stock opened at $3.61 on Tuesday. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 15.70 and a beta of 0.16. Alvotech has a 12 month low of $3.45 and a 12 month high of $11.85. The firm has a 50 day moving average of $4.61 and a two-hundred day moving average of $5.96.

Wall Street Analyst Weigh In

Several research analysts have commented on ALVO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research report on Wednesday, January 21st. UBS Group decreased their price objective on Alvotech from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wall Street Zen lowered shares of Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Barclays began coverage on Alvotech in a research note on Monday, December 8th. They issued an “underweight” rating and a $5.00 price objective on the stock. Finally, Zacks Research lowered shares of Alvotech from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $8.60.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALVO. Goldman Sachs Group Inc. grew its stake in Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after purchasing an additional 122,089 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Alvotech by 10.7% in the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after buying an additional 24,667 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Alvotech in the fourth quarter valued at approximately $474,000. Invesco Ltd. boosted its stake in shares of Alvotech by 57.5% during the 4th quarter. Invesco Ltd. now owns 73,360 shares of the company’s stock worth $376,000 after acquiring an additional 26,784 shares during the period. Finally, Citadel Advisors LLC bought a new position in Alvotech during the third quarter worth $346,000.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).